
|Videos|July 7, 2020
Expanding Options for Relapsed/Refractory HER2+ Metastatic Breast Cancer
Author(s)Targeted Oncology
Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
4
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
5


































